- Report
- August 2023
Europe
From €12783EUR$14,500USD£11,228GBP
- Report
- August 2023
Asia Pacific
From €8375EUR$9,500USD£7,356GBP
- Report
- August 2023
Global
From €24244EUR$27,500USD£21,294GBP
- Report
- November 2025
- 132 Pages
Global
From €838EUR$950USD£736GBP
- Report
- March 2024
- 132 Pages
Global
From €838EUR$950USD£736GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more